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Background: Primary pulmonary synovial sarcoma (PPSS) is rare. We describe a case of PPSS complicated by tibial
adamantinoma that required differentiation from lung metastasis.
Case presentation: A 39-year-old Japanese woman presented with hemoptysis, dyspnea, and a well-defined tumor
measuring 3.0 cm in greatest diameter in the right lower lobe on chest computed tomography (CT). Positron emission
tomography/CT with fluorodeoxyglucose (FDG-PET/CT) showed mild uptake of FDG (maximum standardized uptake
value of 2.0). Her past history included surgery for adamantinoma of the right tibia at age 25 years. We considered the
possibility of pulmonary metastasis from the adamantinoma and performed fluoroscopy-assisted thoracoscopic
resection of the tumor after CT-guided Lipiodol marking. Histologically, the tumor was composed mainly of a
dense proliferation of spindle cells. Immunohistochemical studies were positive for epithelial membrane antigen,
B cell lymphoma 2, and transducing-like enhancer of split 1. They were negative for CD34. The synovial sarcoma,
X breakpoint 1 gene-fusion transcript was detected by reverse transcription-polymerase chain reaction. It is diagnostic
of PPSS. Resection margins were negative. The patient was well without evidence of recurrence or metastasis of the
PPSS or adamantinoma at the 30-month and 15-year follow-ups.
Conclusion: Clinical and radiological manifestations of PPSS overlap with those of other lung tumors. The solitary
pulmonary nodule in this case was indistinguishable from pulmonary metastases of the adamantinoma based on
clinical symptoms, epidemiology, chest radiography, CT, and FDG-PET/CT. PPSS was diagnosed only after evaluating
gross pathology, histology, immunohistochemistry, and cytogenetics. PPSS should be included in the differential
diagnosis of a well-defined homogeneous round or oval lung mass. To our knowledge, this is the first report of PPSS
complicated by adamantinoma.
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Most lung tumors are malignant, carcinomatous metasta-
ses from other tissue cancers, such as bone tumors. Pri-
mary lung sarcoma is rare, accounting for less than 0.5% of
all lung tumors [1,2]. The variety of soft tissue sarcomas re-
flects the range of mesenchymal tissues present in the lung.* Correspondence: shi-ra-e@koto.kpu-m.ac.jp
1Department of Orthopaedics, Graduate School of Medical Science, Kyoto
Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto
602-8566, Japan
2Department of Orthopaedic Surgery, Graduate School of Medical Science,
Kanazawa University, 13-1 Takara-machi, Kanazawa, 920–8641, Japan
Full list of author information is available at the end of the article
© 2014 Shirai et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.These sarcomas include extraskeletal Ewing’s sarcoma,
malignant fibrous histiocytoma, and synovial sarcoma. The
latter is a rare sarcoma accounting for approximately 8% of
soft tissue sarcomas. Although synovial sarcoma predom-
inantly affects the extremities of young adults, primary
lesions have also been identified in the head and neck,
abdominal wall, and thorax (including the mediastinum,
pericardium, pleura, and lung) [3-5]. A recent MEDLINE
search revealed approximately 92 cases of primary
pulmonary synovial sarcoma (PPSS) reported worldwide
during the last three and a half decades. There were no
reports, however, of PPSS complicated by a primary bonetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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differentiation from tibial adamantinoma metastasis.Case presentation
Initial presentation and diagnostics
A 39-year-old Japanese woman, who was a household
helper, presented to a community hospital with hemoptysis
and dyspnea. Other symptoms, such as cough and chest
pain, were not presented. She reported a family history of
stomach cancer (her father). She had smoked one or
two cigarettes daily for the last 19 years. There was no
history of asbestos exposure or tuberculosis. She had
undergone wide resection of an adamantinoma of the
right tibia and limb salvage with an uncemented mega-
prosthesis (Howmedica Modular Replacement System;
Howmedica International, Limerick, Ireland) 15 years
previously (Figure 1). Her vital signs and clinical exam-
ination results were unremarkable. A general survey re-
vealed no clubbing and no palpable cervical or axillary
lymph nodes. Sputum was negative for acid-fast bacilli.
The serum tumor marker levels were within their re-
spective normal ranges.Figure 1 Postoperative radiographs of tibial adamantinoma.
Anteroposterior and lateral radiographs show the uncemented
megaprothesis (Howmedica Modular Replacement System) used to
treat the patient after prior resection of an adamantinoma of the
right tibia. No evidence of recurrence is present.Chest radiography demonstrated a mass in the right
lower field without pleural effusion. Computed tomog-
raphy (CT) of the lung revealed a mass measuring 2.5 ×
3.0 cm that had no contact with the pleura, main bron-
chus, inferior pulmonary vein, or right atrium (Figure 2a).
Bronchoscopy did not reveal any abnormalities. Positron
emission tomography (PET)/CT with fluorodeoxyglu-
cose (FDG) showed mild FDG uptake, with a maximum
standardized uptake value (SUVmax) of 2.0 (Figure 2b).
Treatment
Because the tumor was suspected to be a pulmonary
metastasis from the earlier adamantinoma, we surgically
resected it without prior biopsy. The procedure was as
follows. The pulmonary nodule was marked with 0.4 mL
of Lipiodol® (Laboratoire Guerbet, Roissy, France) under
CT guidance. The visceral pleura near the nodule was
marked with 1 mL of a mixture of atelocollagen and
methylene blue. During the thoracoscopic surgery per-
formed 1 day later, the marked nodule was grasped with
ring-shaped forceps under C-arm fluoroscopic guidance
and resected [6,7].
Histology
Histopathologically, the tumor showed densely prolifer-
ated spindle cells with a high mitosis rate (Figure 3a).
The immunohistochemical workup revealed that the
spindle cell component was positive for B cell lymphoma
2 (BCL-2), pancytokeratin (MNF116) directed to cytokera-
tins 5, 6, 8, 17, and 19, transducin-like enhancer of split 1
(TLE-1), and epithelial membrane antigen (EMA). It was
negative for CD34 (Figure 3b-d). The synovial sarcoma, X
breakpoint 1 (SYT-SSX1) fusion gene was detected by
reverse transcription-polymerase chain reaction using
ribonucleic acid samples from the tumor tissue. Hence, the
final diagnosis was PPSS. Resection margins were negative.
Follow-up
The patient’s hemoptysis and dyspnea resolved after the
surgical procedure. Because the patient had factors indicat-
ing a poor PPSS prognosis, including her age (>20 years),
sex, and the presence of the SYT-SSX1 variant gene, we
recommended chemotherapy with a combination of ifosfa-
mide and doxorubicin. She refused further treatment, how-
ever. Follow-up visits were undertaken every 3 months
after the surgery. She has remained well without evidence
of recurrence or metastasis of the PPSS or the adamanti-
noma at the 30-month follow-up.
Discussion
Soft tissue synovial sarcoma is a clinicopathologically
and cytogenetically distinctive neoplasm that mainly
affects deep soft tissues of the extremities in adolescents
and young adults. Synovial sarcoma is also recognized as
a b
Figure 2 Preoperative computed tomography and positron emission tomography with fluorodeoxyglucose. Axial section of computed
tomography (a) and positron emission tomography/computed tomography with fluorodeoxyglucose (b) show slightly high uptake by the right
lung mass (arrow).
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sive tumor whose histological features are also seen in
soft tissue synovial sarcoma [9]. PPSS occurs in older
patients as well, however, in contrast to other soft tissue
synovial sarcomas, with patients’ ages ranging from 9 to
84 years (mean 43 years) without sex bias [3-5]. Hartel
et al. [10] reported that clinical symptoms are dyspnea
(42%), chest pain (39%), cough (32%), and hemoptysis
(22%). There are few asymptomatic cases. Most PPSSs
are located in the lung parenchyma (58%), pleura (33%),
and mediastinum (9%). Rarely, they extend into the bron-
chial tree or occur in the heart or pericardium [3,4,8,11].
PPSS lesions range in size from 0.6 to 27.0 cm (mean
6.8 cm) [4,10]. Radiologically, in contrast to soft tissue
synovial sarcoma, PPSS is typically uniform with well-
circumscribed rounded or lobulated borders [12,13]. TheFigure 3 Histology. (a) Photomicrograph shows histopathological feature
spindle cells positive for the presence of CD34, transducin-like enhancer ofcontralateral lung usually appears normal, although medi-
astinal shift may occur in the presence of an extremely
large mass [11]. CT demonstrates a well-defined homoge-
neous or heterogeneously enhancing mass containing
necrotic areas and soft tissue components with common
ipsilateral pleural effusion [11,12]. Similar to all sarcomas,
metastasis occurs via the blood, and adenopathy is
uncommon. Endobronchial invasion is also not common,
unlike lung carcinoma [11,14]. Because of their high meta-
bolic activity, these lesions show increased FDG uptake
(SUVmax of > 2.5) on PET/CT [15].
Adamantinoma, in contrast, is a low-grade neoplasm
that affects long bones and accounts for less than 1% of
all primary bone tumors. These lesions occur most com-
monly in patients 10–50 years of age with slight male
preponderance [16,17]. They are locally aggressive. Thes of spindle cell sarcoma (H&E, ×20). (b-d) Photomicrograph shows
split 1, and pancytokeratin.
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of metastases ranges between 10% and 20% [16,17]. They
are capable of sending off distant metastases, especially
to the lung [18]. It is not uncommon to develop pul-
monary metastases even up to 10 years after detection of
the primary lesion [19]. Radiologically, the tumor is
typically uniform, well circumscribed, and similar to
other pulmonary metastases of bone tumors. Pulmonary
metastases of adamantinomas range in size from 0.4 to
10.0 cm (mean 4.7 cm) [16-19].
We considered pulmonary metastasis of adamanti-
noma in the differential diagnosis of our case because of
the CT and FDG-PET/CT findings, the past history of
adamantinoma, and the lack of reports of PPSS in con-
junction with another tumor in the literature. Metasta-
tectomy to remove pulmonary adamantinoma lesions
with good results has been reported [19]. There appears
to be no definitive role for radiotherapy or chemother-
apy [20]. We therefore performed fluoroscopy-assisted
thoracoscopic resection of the small pulmonary tumor
in our patient. Unexpectedly, the final diagnosis based
on histological findings and cytogenetic analysis was
PPSS. Matsuo et al. [21] concluded that, although rare,
PPSS should be included in the differential diagnosis of
a well-defined homogeneous, round lung mass on CT
images. However, the clinical and radiological manifesta-
tions of PPSS overlap with those of other lung lesions,
including malignant melanoma, epithelioid schwan-
noma, malignant fibrous histiocytoma, malignant meso-
thelioma, adenocarcinoma, carcinosarcoma, lung hydatid
disease, metastatic carcinoma, bronchogenic carcinoma,
mesothelioma, lymphoma, Wegener’s granulomatosis,
pyogenic abscess, intrapulmonary hematoma, rheuma-
toid nodules, histoplasmosis, coccidioidomycosis, and
bone tumor metastasis [15,22]. These primary lung le-
sions are typically indistinguishable from PPSS based on
clinical symptoms, epidemiology, chest radiography, CT,
and FDG-PET/CT [12,23]. To reach a correct diagnosis,
the t(X; 18)(p11.2;q11.2) chromosomal translocation
should be demonstrated by cytogenetic testing. This analysis
is the only primary test for diagnosing synovial sarcoma
[9,15]. According to Akerman et al. [24], the diagnosis of
synovial sarcoma in large lesions (>3 cm) may be suggested
in fine-needle aspiration biopsy specimens, but adjunctive
methods are necessary for a definitive diagnosis. As a result,
it may be that only after surgery is it possible to diagnose a
small PPSS that has no contact with other internal organs,
as in our case.
Because of its rarity and the paucity of data regarding its
natural history, there are no guidelines regarding the opti-
mal treatment for PPSS. Current treatment thus includes
surgical resection (lobectomy or pneumonectomy) [25]. In
our case, complete surgical excision of PPSS was per-
formed by fluoroscopy-assisted thoracoscopic resection.Patient age, a positive surgical margin, and tumor size
help guide the decision about whether additional adju-
vant chemotherapy and/or radiation therapy is needed
[25]. The overall 5-year survival rate for those with
PPSS is 50%. Factors that indicate a poor prognosis in-
clude age >20 years, female sex, tumor size >5 cm, posi-
tive resection margin, extensive tumor necrosis, high
number of mitoses (>10 per 10 high-power fields), neu-
rovascular invasion, and the presence of the SYT-SSX1
variant gene [25]. Although our patient had several fac-
tors that put her at risk of a poor prognosis, she experi-
enced no recurrence during 30 months of postoperative
follow-up.
We had recommended that our patient undergo
chemotherapy with ifosfamide and doxorubicin, but she
refused further treatment. We also suggested pazopanib,
which interferes with vascular endothelial growth factor
and platelet-derived growth factor pathways. Pazopanib
is the first nonchemotherapeutic anticancer agent ap-
proved by regulatory authorities for soft tissue sarcoma
and to which pulmonary adamantinoma metastasis
responds [26,27]. Long-term follow-up is necessary for
patients with a soft tissue sarcoma.
Conclusions
This is the first report of PPSS complicated by tibial ada-
mantinoma, which is a low-grade malignant primary bone
tumor. PPSS is a rare tumor without specific symptoms,
signs, or radiological features. The role of functional im-
aging has not yet been evaluated, and the diagnosis is usu-
ally based on histopathological examination or cytogenetic
testing of the resected tumor. The diagnosis of PPSS
before surgery also may not be possible, as in our patient.
Along with pulmonary metastasis from a bone tumor,
PPSS should be included in the differential diagnosis of a
well-defined homogeneous round or oval lung mass.
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